CLXPF News and Press, Canadian Lynx Pete Ltd From 06/22/21

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the completion of its 51 st pre-clinical study as it continues to progress its p...

NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and ...

A report published recently in PLOS One revealed that the symptoms of mental health conditions affected how individuals responded to being placed in subordinate and dominant positions. The research stated that depressive and manic symptoms especially were linked to physiological and psyc...

The study will examine treating symptoms of depression, anxiety, burnout and post-traumatic stress EMBARK is groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine Cybin considers it an honor, duty to supp...

Cybin (CLXPF) announces that it has selected social anxiety disorder (“SAD”) and generalized anxiety disorder (“GAD”) as the initial target indications for its proprietary psychedelic molecule CYB004.Various studies reviewing the improvements in anxiety with p...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has selected social anxiety disorder (“SAD”) and generalized a...

Investing in medicinal psychedelic research in the recent past was considered risky. Now, however, financiers and entrepreneurs are injecting money into the development of psychedelic therapies for behavioral and mental health issues. Despite this, one of the biggest public financiers of...

According to recently released research , patients who suffer from inflammatory bowel disease and major depressive disorder have higher healthcare burdens and discharge rates, as well as increased morbidity. Major depressive disorder, which is sometimes referred to as clinical depression,...

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, will be part of the upcoming H.C. Wainwright Psychedelics in Psychiatry and Beyond conference. The all-virtual conference is slated for June 17, 2021. During the conference, Cybin CEO...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the H.C. Wainwrig...